Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
MWN-AI** Summary
Psyence Biomedical Ltd. (Nasdaq: PBM), a biopharmaceutical company focusing on nature-derived psilocybin and ibogaine therapies for mental health, announced the results of its Annual and Special Meeting of Shareholders held on February 12, 2026. The meeting yielded unanimous support from shareholders for all agenda items, highlighting strong confidence in the company's leadership and strategic direction.
Key outcomes included the election of all nominated directors as outlined in the company's management information circular dated January 2, 2026. MNP LLP was appointed as the auditors for the upcoming year, with authorization granted for the Board to set their remuneration. Notably, shareholders approved a special resolution permitting the Board to execute a share consolidation of up to 250:1 at their discretion. This consolidation could potentially affect the Company’s capital structure and will be communicated with further details once a decision is made, subject to regulatory approvals.
Psyence BioMed positions itself as a pioneer in the biotech sector, being the first life sciences firm dedicated to developing non-synthetic psychedelic medicines listed on Nasdaq. The company aims to address pressing mental health needs through evidence-based, FDA-approved treatments, reflecting its commitment to innovation in psychedelic therapeutics.
The meeting’s results are an essential step in the company’s ongoing development of its product pipeline and represent solid backing from shareholders. However, as with many biopharmaceutical ventures, Psyence BioMed faces uncertainties, particularly concerning future clinical trials and regulatory compliance. The company emphasizes caution regarding forward-looking statements and highlights the need for rigorous clinical research to substantiate claims surrounding its therapies. For detailed information on risks and future plans, stakeholders can refer to filings made with the SEC.
MWN-AI** Analysis
Psyence Biomedical Ltd. (Nasdaq: PBM) recently held its Annual and Special Meeting of Shareholders, where key matters were voted on and approved, including the appointment of auditors and the controversial share consolidation authority. The approval of a share consolidation, which could occur at a ratio of up to 250:1, raises red flags for retail investors and warrants caution. While consolidation can be a strategic move aimed at increasing share price and improving the attractiveness of the stock for institutional investors, it can also create volatility that may impact market sentiment negatively.
Given Psyence's focus on developing nature-derived psilocybin and ibogaine therapies, it operates in a highly specialized sector characterized by regulatory scrutiny and competition. Approval of its drug candidates is contingent on rigorous clinical trials, and any setbacks in this area could provoke significant market repercussions. Furthermore, investor confidence must be maintained, and the company is mandated to comply with Nasdaq's listing standards, emphasizing the importance of operational transparency.
Investors should closely monitor developments related to the proposed share consolidation, as the timing and implementation can significantly affect share liquidity and market behavior. This could result in short-term price volatility, as observed in other cases of consolidation. A delayed or poorly executed consolidation may deter investors, particularly in light of existing uncertainties within the broader psychedelic industry.
In conclusion, while Psyence has established itself as a pioneering entity within psychedelic therapeutics, the recent corporate governance decisions raise questions. Investors should remain vigilant, evaluate their risk tolerance, and analyze market trends and developments within the sector before making any investment decisions. It may also be wise to seek diversified exposure in biopharmaceutical stocks, reducing reliance on a single entity during this formative phase.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “Board”).
All director nominees listed in the Company’s management information circular dated January 2, 2026 were duly elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Shareholders approved the appointment of MNP LLP as the Company’s auditors for the ensuing year and authorized the Board to fix the auditors’ remuneration. Shareholders further approved a special resolution authorizing the Board, in its sole discretion, to implement one or more consolidations of the Company’s issued and outstanding common shares, at a ratio of up to 250:1, with such consolidation(s) to be implemented, if at all, at a time and ratio to be determined by the Board.
The Company will provide additional disclosure if and when the Board determines to implement any share consolidation, including the final consolidation ratio and effective date, subject to applicable regulatory and exchange approvals.
Further details regarding the matters voted on at the Meeting are set out in the Company’s management information circular, which is available under the Company’s profile on EDGAR.
About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Learn more at www.psyencebiomed.com and on LinkedIn.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Investor Contact:
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.
Forward-looking statements in this communication include statements regarding the discretion of the Board to implement a share consolidation of the Company's issued and outstanding common shares. These statements are based on current assumptions and expectations, including assumptions regarding the Company’s ability to maintain compliance with Nasdaq’s continued listing standards. These assumptions may prove incorrect. There can be no assurance as to when a share consolidation will be implemented, if at all. There are numerous risks and uncertainties that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, among others: (i) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (ii) potential volatility in the Company’s share price following the results of the Meeting; (iii) changes in the regulatory, competitive, and economic landscape; and (iv) risks associated with the Company’s development plans and clinical trials. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.
These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
FAQ**
How does Psyence Biomedical Ltd. (PBM) plan to implement the share consolidation authorized by shareholders, and what potential impacts could that have on its stock market performance?
Given the current regulatory landscape, how does Psyence Biomedical Ltd. (PBM) ensure compliance with Nasdaq's continued listing standards moving forward?
What clinical trials or research does Psyence Biomedical Ltd. (PBM) plan to conduct to validate the safety and efficacy of its psilocybin and ibogaine therapies?
How might the recent shareholder approvals impact Psyence Biomedical Ltd. (PBM)’s strategic direction and product development in the coming year?
**MWN-AI FAQ is based on asking OpenAI questions about Psyence Biomedical Ltd. (NASDAQ: PBM).
NASDAQ: PBM
PBM Trading
2.74% G/L:
$2.5788 Last:
22,253 Volume:
$2.50 Open:
